Statement of Principles concerning malignant neoplasm of the stomach (Reasonable Hypothesis) (No. 74 of 2023)

The Statement revolves around a small set of legal-medical concepts that structure how decision-makers will evaluate claims: the defined disease entity; the "reasonable hypothesis" evidentiary threshold; enumerated causal factors with quantitative and temporal thresholds; the relationship of those factors to relevant service; and cross-reference to other Statements of Principles. Each concept is given a statutory location and a narrow textual definition in the instrument.

1. Defined disease entity: "malignant neoplasm of the stomach" is defined to mean a primary malignant neoplasm arising from epithelial cells of the stomach, with explicit exclusions listed (s7(2)(a)-(b)). The instrument notes that while ICD‑10‑AM code C16 commonly labels stomach cancer, the Statement uses its own statutory definition (s7(3)-(4)). The definition includes death that was contributed to by the neoplasm (s7(5)) and clarifies "terminal event" in the Schedule 1 dictionary.

2. Reasonable hypothesis threshold: Section 9 sets the evidentiary content of a "reasonable hypothesis" connection. The instrument does not redefine the legal standard of "reasonable hypothesis" itself, but it prescribes the factors which, when established and linked to relevant service, are sufficient to say that a reasonable hypothesis has been raised (s9). The RMA explicitly states this is informed by "sound medical‑scientific evidence" (s8).

3. Enumerated factors and thresholds: There are 23 discrete factors (s9(1)-(23)). Each factor contains numeric or temporal thresholds and often both. Examples of measurement units used are pack-years (schedule definition), sieverts for ionising radiation (s9(2) and Schedule 1 definition of cumulative equivalent dose), kilograms of alcohol (s9(6)), grams per day of preserved vegetables or processed meat (s9(8), s9(11)), hours of exposure to respirable asbestos or crystalline silica in enclosed or open environments (s9(13)-(14), s9(20)-(21)), durations for infections (H. pylori and Epstein-Barr at least ten years before clinical onset: s9(3), s9(15)), durations for chronic conditions (diabetes mellitus for at least five years prior: s9(16); chronic atrophic gastritis commencing at least two years before onset: s9(4)), and drug exposure windows for proton pump inhibitors for non-cardia carcinoma (s9(19)).

4. Temporal relation to clinical onset: Most factors require the exposure or condition to have existed a minimum number of years before the clinical onset of the neoplasm; some require cessation windows (for example smoking cessation: onset within 25 years of cessation) (s9(1)). The instrument repeatedly ties the causal link to the dating of "clinical onset" and, in the case of death, to "death from a terminal event or condition that was contributed to by the person's malignant neoplasm of the stomach" (s7(5)).

5. Relationship to relevant service: Any factor relied upon must be related to the person's relevant service as defined in the Schedule 1 dictionary (s10(1); Schedule 1 defines "relevant service" by reference to categories under the VEA and MRCA). Factor 9(23) has a special condition: it applies only when the neoplasm was suffered or contracted before or during (but did not arise out of) the person's relevant service (s10(2)).

6. Cross-referencing to other Statements: Where a factor refers to another injury or disease that itself has a Statement of Principles, that other Statement applies (s11). This creates a modular evidentiary network: establishing, for example, an infectious disease factor may require reference to a separate SOP.

7. Technical measurement standards: The Schedule supplies technical definitions and points to external methodology for dose calculation: cumulative equivalent dose is to be calculated in accordance with the ARPANSA Guide as in force on 2 August 2017 (Schedule 1). The pack-year definition supplies an exact gram-equivalent conversion for tobacco.

These concepts combine to create an evidence architecture: decision-makers will check whether an applicant has a condition that fits the statutory definition, then whether at least one of the listed factors, proved to the temporal/quantitative thresholds and linked to relevant service, exists. The instrument therefore translates medical-scientific findings into administrable evidentiary predicates for claims.

The Statement directly affects three groups of people and multiple administrative actors. First, veterans, members of Peacekeeping Forces, and members of the Forces who lodge claims under section 120A of the VEA or section 338 of the MRCA are within the instrument’s ambit (s5). Those claimants who have or have died from a primary epithelial malignant neoplasm of the stomach, as defined in s7(2), will be specifically affected because the Statement sets out what must be shown to raise a reasonable hypothesis that the disease is related to relevant service (s9).

Second, the administrative decision-makers who process VEA and MRCA claims , typically the Department of Veterans' Affairs (DVA) and its delegates , will be required to apply this instrument as the evidentiary guidance for the "reasonable hypothesis" test in the statute. While the Statement itself does not specify how those decision-makers are to use it, s5 makes its application explicit to claims under the cited statutory provisions. The Repatriation Medical Authority made the Statement under its statutory power (s3). The RMA characterises the Statement as founded on sound medical-scientific evidence (s8), signalling that it is intended to guide medically-based administrative determinations.

Third, medical practitioners, occupational hygienists, radiation dose reconstruction specialists, and medico-legal experts who prepare evidence in support of claims will be affected because the Statement prescribes precise thresholds, units and time periods that evidence must address. For example, to satisfy the radiation exposure factor, evidence must quantify a cumulative equivalent dose to the stomach of at least 0.1 sievert, calculated in accordance with the ARPANSA Guide method cited in the Schedule (s9(2) and Schedule 1). For occupational asbestos or crystalline silica exposures, experts must document cumulative hours in enclosed versus open environments, with exact thresholds (s9(13)-(14), s9(20)-(21)). The Schedule also sets out dietary definitions, BMI ranges for overweight and obese, and gram-conversion for pack-years, all of which constrain how evidence is formulated.

Fourth, employers, superannuation or compensation administrators, and healthcare providers may feel indirect effects. Employers and former employers may be requested to supply employment records, worksite exposure logs or rosters to substantiate cumulative hours of exposure. Pharmacies and clinicians may be asked for dispensing records or treatment notes to support PPI use records (s9(19)). Hospitals and laboratories will be sources of pathology showing H. pylori or Epstein-Barr virus infection with the requisite timing (s9(3), s9(15)). While the instrument does not create new duties on these parties, the practical effect is a demand for documentary evidence from third parties to support claims.

Finally, the instrument affects the character of dispute and appeal work. Because the Statement sets bright-line quantitative thresholds, contested claims may focus on the adequacy of record evidence to meet those thresholds, on timing of clinical onset, on whether a stated exposure is post-service or during service, and on the application of the ARPANSA dose calculation method. Section 11 further implicates those relying on other Statements of Principles: if a claimed factor is itself an injury or disease covered by another SOP, the other SOP's terms will govern, adding layers of cross-referencing to claim preparation and contestation.

Overall, the Statement affects claimants and decision-makers by converting scientific associations into administrable, numeric or time-focused predicates. The practical burden to meet those predicates falls chiefly on claimants and the experts presenting evidence on their behalf; the administrative burden to apply and adjudicate the predicates falls on the decision-making agencies.

The Statement establishes no statutory duties that create criminal or civil penalties within its text. Instead it prescribes the minimal evidentiary factors that must exist before a reasonable hypothesis can be said to link malignant neoplasm of the stomach (or death from it) with a person’s relevant service (s9). As such, the primary "duties" are administrative obligations of decision-makers to apply the Statement in claims covered by s120A of the VEA or s338 of the MRCA (s5), and the practical obligation on claimants to adduce evidence against the thresholds the Statement sets.

Key rights and entailed procedural implications, as governed by the enabling statutes rather than by this instrument itself, are that persons who have relevant service and the disease may apply under the VEA or MRCA. This Statement determines what factual showings are necessary to have a reasonable hypothesis established; it does not define entitlement or quantum. The RMA’s stated basis is "sound medical-scientific evidence" (s8), meaning decision-makers must treat the enumerated factors as the configured evidentiary predicates for a reasonable hypothesis relating the disease to service.

For decision-makers, the Statement imposes a duty to consider whether at least one of the listed factors is present and is connected to service (s9, s10(1)). Where a factor refers to another disease that has its own Statement of Principles, the other Statement applies "in accordance with the terms of that Statement of Principles as in force from time to time" (s11). This creates a duty to cross-reference and apply other Statements where relevant.

For claimants, the Statement functions as a rule of evidence and a roadmap of what must be proved. It effectively requires claimants to establish, with documentation and expert evidence if necessary, that one or more of the factors and their timing thresholds were satisfied and that these factors relate to relevant service (s9, s10). For example, to rely on the smoking factor, claimants must show at least 15 pack-years of tobacco use, starting at least 10 years before clinical onset, and if smoking has ceased, the onset must have occurred within 25 years of cessation (s9(1)). For radiation, a claimant or their experts must show a cumulative equivalent dose of at least 0.1 sievert to the stomach at least five years before clinical onset; the Schedule requires use of the ARPANSA Guide for dose calculation (s9(2); Schedule 1). Thus, claimants bear the practical burden of producing temporally specific medical, occupational, or behavioural evidence.

There is a limited procedural nuance for factor 9(23) - inability to obtain appropriate clinical management. That factor applies only to material contribution or aggravation where the person's malignant neoplasm of the stomach was suffered or contracted before or during but did not arise out of relevant service (s10(2)). This circumscribes how "inability to obtain appropriate clinical management" can be invoked; it is not a free-standing factor where the neoplasm first arose as a result of service.

Rights to appeal, judicial review or reconsideration lie in the underlying statutes and administrative review regimes rather than in this instrument. The Statement itself does not set appeal pathways or penalties; it supplies the evidentiary benchmarks which decision-makers will apply when exercising their statutory functions under the VEA and MRCA. Practically, parties have the right to tender medical and vocational evidence contesting whether the factors and their links to service are established, but the Statement narrows the focal points of such disputes to the factors, their thresholds, timing relative to clinical onset, and the question whether they relate to relevant service as defined.

The Statement itself does not create criminal offences, civil penalties, or direct enforcement mechanisms. It is an evidentiary instrument made under subsection 196B(2) of the VEA (s3) and is descriptive and prescriptive of medical-scientific factors required to raise a reasonable hypothesis that a disease is related to service. There are no penalty provisions, fines, or enforcement procedures set out within the text. Instead, enforcement occurs indirectly through administrative decision-making under the VEA and MRCA.

That is, the practical "enforcement" effect is realised when decision-makers applying the VEA or MRCA accept or reject claims based on whether the factors in s9 are established and connected to relevant service (s5, s9, s10). If a claimant cannot demonstrate at least one of the specified factors in the required temporal and quantitative terms, a decision-maker may find that the reasonable hypothesis threshold is not met, with consequent denial of claim-related entitlements under the governing statute. Any adverse administrative decision will be subject to the existing review and appeal mechanisms under the VEA or MRCA and the broader administrative law framework; however, this Statement does not itself prescribe or modify those statutory review pathways.

Because the Statement maps the medical causation or contribution question into concrete factors, the instrument alters the operational enforcement landscape by narrowing or clarifying the factual elements a claimant must prove. For example, a decision-maker could rely on the lack of documented cumulative exposure meeting the asbestos or crystalline silica hourly thresholds (s9(13)-(14), s9(20)-(21)) as the basis for rejecting the relevant hypothesis. The Statement assigns evidentiary weight to particular forms of proof , quantified pack-years, ARPANSA-guided radiation dose calculations, documented H. pylori infection at least ten years before onset, and so on (s9; Schedule 1). The "penalty" in such cases is administrative non-acceptance of service connection.

Finally, the instrument has a repeal mechanism (s4), replacing the 2014 Statement. The service of repeal is administrative, not punitive. The repeal alters the evidentiary predicates governing new and ongoing claims from the commencement date (s2). Stakeholders should note there is no transitional penalty clause in the Statement; questions about how pre-commencement evidence is to be treated would be resolved under the VEA, MRCA and agency practice rather than within this Statement.

In summary, the Statement creates no direct sanctions; its enforcement effect is mediated by administrative decision-making under the VEA and MRCA, where inability to meet the prescribed factors will have the practical consequence of claim refusal or limitation under the relevant statutory schemes.

This instrument is made under subsection 196B(2) of the VEA (s3) and explicitly applies to claims to which section 120A of the VEA or section 338 of the MRCA applies (s5). Its primary statutory interaction is therefore with the VEA and MRCA statutory frameworks governing veteran entitlements and military compensation. The Statement functions as the RMA's determination of the factors that are to be considered when assessing whether a reasonable hypothesis connects the disease to relevant service. The instrument does not itself amend, suspend or otherwise change obligations or benefits in the VEA or MRCA; rather, it changes the medical-evidentiary determinatives used under those Acts.

The Schedule cross-references external technical guidance: cumulative equivalent dose must be calculated in accordance with the methodology set out in the ARPANSA Guide to calculation of 'cumulative equivalent dose' as in force on 2 August 2017 (Schedule 1). That creates an operational dependency on a non-statutory technical instrument maintained by the Australian Radiation Protection and Nuclear Safety Agency. The RMA thereby imports a technical standard into statutory decision-making without altering or reproducing the technical method itself. For dose reconstructions and expert reports, the ARPANSA Guide becomes an incorporated normative reference point as to calculation methodology.

Section 7(3) and (4) note ICD‑10‑AM coding (C16) but clarify that for the Statement, the statutory definition in subsection 7(2) governs the meaning of malignant neoplasm of the stomach. The instrument therefore interacts with coding standards used in clinical and administrative records but asserts its own definitional primacy for the purposes of claims under the VEA/MRCA.

Section 11 creates explicit cross-instrument interaction: where a factor in s9 refers to an injury or disease that is itself the subject of another Statement of Principles made under subsection 196B(2) of the VEA, that other Statement applies according to its terms in force from time to time (s11). Practically, that means decision-makers must apply a network of Statements: for example, if s9 invokes an infectious disease factor that has its own SOP, the SOP for that infectious disease governs the assessment of that factor. This modularity requires assessors to check the current versions of other SOPs and to sequence their application.

The Statement’s application to claims under s120A VEA and s338 MRCA means it sits inside two parallel statutory compensation systems. The instrument does not merge those systems, but because it applies to both, it drives consistency in how the medical causation question is handled across the two Acts. The Statement does not, however, prescribe procedural elements of claim processing, nor does it alter appeals, review rights or statutory timebars in the VEA or MRCA; those remain governed by the statutes and associated regulations.

Finally, because many of the factors rely on clinical or occupational records, the Statement will interact in practice with privacy and evidence laws (for example, the need to obtain medical records, employment records, and pharmacy dispensing records). The instrument itself does not address disclosure rules, but its practical requirements make such interactions likely during claim gathering and adjudication.

In short, the Statement operates as a technical, evidentiary overlay on the VEA and MRCA decision-making apparatus. It imports a technical standard for radiation dose calculation, it cross-references and defers to other Statements of Principles, and it displaces ICD-10 coding by its own statutory definition for the covered condition. Procedural rights and statutory remedies outside the Statement remain governed by the enabling statutes.

The instrument records a single explicit amendment event within its own terms: it repeals the previous Statement of Principles concerning malignant neoplasm of the stomach No. 58 of 2014 (s4). The new Statement is dated 23 June 2023 and commences on 25 July 2023 (s2 and front matter). Beyond that repeal, no earlier amendments to this specific instrument are recorded in the text provided.

The Schedule 1 dictionary cites external material by reference and fixes a version date for that material: the ARPANSA Guide to calculation of 'cumulative equivalent dose' is specified "as in force on 2 August 2017" (Schedule 1). By embedding that dated reference, the instrument effectively anchors one element of its technical methodology to a specific edition of an external technical guide. Changes to that external guide after 2 August 2017 are not incorporated by the text as provided; the Schedule’s wording limits the applicable ARPANSA methodology to the version "as in force on 2 August 2017." Any subsequent amendment to the ARPANSA Guide would, unless otherwise adopted by the RMA in a revised Statement, not alter the dose calculation approach required by this instrument.

The Schedule also defines terms with built-in intervals (for example, definitions of BMI ranges, pack-year equivalences, categories of relevant service), which will remain operative unless the RMA issues a new or amended Statement. Section 11 contemplates that other Statements of Principles may be "in force from time to time," meaning cross-referenced SOPs may be updated and their current terms applied to factors that reference them (s11). Thus, while this Statement has a discrete repeal of the 2014 version and a fixed commencement date, its practical interface with other SOPs and an external technical guide means that changes elsewhere may affect its application even without internal amendment.

Practically, stakeholders should assume: (a) the 2014 Statement has been replaced from 25 July 2023 by this instrument; (b) the ARPANSA methodology is anchored to its 2 August 2017 version as the method for cumulative equivalent dose calculation unless and until the RMA says otherwise; and (c) if other Statements of Principles are amended, those amendments apply to this Statement’s factors whenever s11 refers to another Statement of Principles.

No other amendment history (such as prior variations, transitional provisions, or sunset clauses) is recorded in the instrument provided. The instrument therefore stands as the current RMA determination from its commencement date forward until further RMA action repeals or amends it.

The instrument as provided contains no references to litigation, court decisions, or tribunal determinations. It does not cite cases, nor does it purport to interpret any judicial authority. The text confines itself to the RMA's determination and to the statutory power under subsection 196B(2) of the VEA (s3). Because the Statement is an administrative determination aimed at setting evidentiary benchmarks for claims, any litigation that touches its operation will arise from disputes under the enabling statutes , the VEA and the MRCA , and from the application of administrative law remedies to decisions that take the Statement into account. The instrument does not itself document any such litigation, nor does it invoke judicial authorities.

Given the Statement's role as a piece of decisional guidance for claim adjudication, likely areas of contestation in litigation or review would concern: (a) whether the relevant decision-maker correctly applied the Statement's factors and thresholds to the evidence; (b) whether the factual record met the quantifiable standards in s9; (c) the correct identification of the clinical onset date; and (d) the application of cross-referenced Statements of Principles under s11. However, these are analytical points arising from the operation of the Statement and not items recorded as existing litigation within the instrument.

Practitioners should note that disputes over the interpretation or application of technical terms in the Schedule, such as "cumulative equivalent dose" and the adopted ARPANSA methodology as at 2 August 2017, could be a focus in contested cases, as could the precise anatomical and histological definitions distinguishing cardia from non-cardia stomach carcinoma (Schedule 1). Because the Statement prescribes exact numeric thresholds , for pack-years, sieverts, cumulative hours of asbestos or crystalline silica exposure, grams per day of preserved vegetables, and kilogram totals for alcohol consumption , litigation may emerge when parties clash over the sufficiency or reliability of the evidence used to demonstrate those thresholds. The Statement itself, however, records no litigation history.

If parties seek judicial review of decisions informed by this Statement, the relevant legal questions would be framed by the VEA/MRCA statutory regimes and the administrative law principles applicable to that context. The Statement does not purport to alter judicial review standards or to displace statutory decision-making structures. For definitive information about any litigation that arises after commencement, one must consult court and tribunal dockets and decisions; such material does not appear in the text of the Statement.

The Statement contains several technical thresholds, timings and cross-references that create specific evidentiary hazards and potential pitfalls for claimants and their advisers. These "gotchas" are matters where a close reading of the text is necessary because small differences in interpretation or documentary practice can determine whether a factor is established.

1. Disease definition diverges from ICD coding: The Statement says malignant neoplasm of the stomach attracts ICD‑10‑AM code C16, but for applying the Statement the statutory definition in s7(2) controls (s7(3)). That means a clinical record coded C16 is not automatically sufficient if the tumour falls into one of the listed exclusions (neuroendocrine tumours, gastroblastoma, haematolymphoid tumours, malignant melanoma, mesenchymal tumours) (s7(2)(b)). Practitioners must ensure pathology confirms a primary epithelial tumour and that excluded histologies are ruled out.

2. Clinical onset is pivotal: Many factors hinge on the timing of "clinical onset." The instrument repeatedly ties exposures and infections to specified intervals before clinical onset (for example, H. pylori at least 10 years before onset (s9(3)), radiation at least 5 years before onset (s9(2))). What constitutes "clinical onset" will be contested: symptom onset, diagnostic confirmation, histological diagnosis, or date of first medical presentation? The Statement does not define "clinical onset" beyond its repeated use, so claimants must be careful to document and justify the chosen onset date.

3. Quantified thresholds require precise evidence: Several factors use units that require conversion and precise quantification. The smoking factor uses pack-years with a detailed grams-based equivalent (Schedule 1). The alcohol factor requires demonstrating consumption of at least 400 kilograms of alcohol before clinical onset (s9(6)). Using the Schedule's 10 grams per standard drink conversion, that 400 kilogram threshold is a high total and will be a challenging evidentiary mountain without robust longitudinal history. Processed meat, preserved vegetables, and fermented soy factors require gram-per-day or frequency thresholds sustained for at least 5 consecutive years within a 20-year window (s9(7)-(11)). Dietary recall over long periods is a weak evidentiary base unless supported by contemporary records.

4. Asbestos and crystalline silica exposure measured in cumulative hours and environment: The Statement differentiates enclosed versus open environments and sets different cumulative hour thresholds for asbestos and crystalline silica inhalation (asbestos enclosed 1,000 hours, open 3,000 hours; silica enclosed 1,500 hours, open 3,000 hours) (s9(13)-(14), s9(20)-(21)). Establishing whether exposure was in an enclosed or open environment and calculating cumulative hours requires detailed employment records, task logs and expert reconstruction. Generic workplace roles will often be insufficient.

5. Radiation exposure requires ARPANSA methodology: The cumulative equivalent dose must be calculated per the ARPANSA Guide "as in force on 2 August 2017" (Schedule 1). Dose reconstruction must adopt that methodology; expert reports using different methods could be rejected as non-compliant with the Schedule. That imposes a procedural requirement on expert evidence.

6. Non-cardia versus cardia distinctions matter: Some factors apply only to non-cardia carcinoma (processed meat and PPI use) or only to cardia carcinoma (being overweight or obese) (s9(11), s9(12), s9(19)). The Schedule defines these anatomical and histological distinctions. Pathology reports must specify tumour site and histological features (presence of cardiac glands, absence of parietal and chief cells) to fit within the designated factor categories.

7. PPI window nuance: The PPI factor for non-cardia carcinoma requires continuous use for at least 1 year within the 5 years before clinical onset, and the last dose must have been taken at least 1 year before clinical onset (s9(19)). That combination , use window within five years but cessation at least one year before onset , is a very specific temporal pattern. Pharmacies' dispensing records and clinician notes must match that pattern precisely.

8. Factor 9(23) limitation: Inability to obtain appropriate clinical management applies only where the neoplasm was suffered or contracted before or during, but did not arise out of, relevant service (s10(2) and s9(23)). That restriction narrows the contexts where inability to obtain treatment can be relied upon and requires careful chronological mapping of disease acquisition versus service.

9. Cross-referenced SOPs: If a factor in s9 refers to another disease with its own SOP, the other SOP applies "as in force from time to time" (s11). That means assessors and claimants must track other Statement versions and ensure any referenced disease is proved in accordance with its current Statement. Failing to do so can lead to evidence being non-compliant or incomplete.

10. High numeric thresholds create evidentiary bottlenecks: Examples include 15 pack-years for smoking (with gram equivalents supplied), 0.1 sievert for radiation, 400 kilograms of alcohol, weekly opium for at least 10 years, and substantial cumulative exposure hours for asbestos and silica. These thresholds are often high and will disqualify many claimants who lack long-term or well-documented exposure histories.

11. The Schedule defines terms tightly: Definitions of "being overweight," "being obese," "one pack-year," "allium vegetables," "fermented soy products," "preserved vegetables," and "processed meat product" have precise meanings (Schedule 1). Expert and documentary evidence must align with these definitions. For example, processed meat products are explicitly listed as including ham, frankfurters, salami and bacon (Schedule 1), so more ambiguous food items will require expert classification.

In practice, these gotchas mean claimants and their advisers must pay particular attention to the documental chain, to choosing and justifying clinical onset dates, to obtaining expert reports that use the prescribed technical standards, and to assembling occupational and pharmacy records that can substantiate the precise temporal and quantitative thresholds in s9. Failure to address these specifics can result in a claim failing the reasonable hypothesis test even where a non‑quantified association might exist clinically.

Compliance, in the context of this Statement, means structuring claims and evidentiary material so that at least one of the factors listed in s9 is demonstrably met and related to the person’s relevant service (s9, s10(1)). The following practical steps map the Statement’s textual requirements to concrete evidentiary actions for claimants, medical advisers and administrators.

1. Confirm diagnosis and histology per s7(2): Obtain full pathology reports that show a primary epithelial malignant neoplasm of the stomach. Ensure reports specify tumour site (cardia versus non-cardia) and histological features. If histology suggests an excluded category listed in s7(2)(b) (for example, neuroendocrine tumours or lymphoma), the condition will not fall within this Statement. If coding shows ICD‑10‑AM C16, do not rely on code alone; secure the underlying histopathology that matches the statutory definition (s7(2)-(4)).

2. Fix and document "clinical onset": Make an evidentiary decision as to what is being treated as clinical onset (first symptoms, first diagnostic test, biopsy date, radiological detection). Document the rationale and secure contemporaneous medical records to support that date because multiple s9 factors are timed to "clinical onset" (s9).

3. Select applicable factor(s) and map evidence: Review the 23 factors in s9 and identify which can realistically be proved. For the chosen factor, assemble the targeted documentary evidence aligned to the numerics and timing. Examples:

   • Smoking (s9(1)): calculate pack‑years using Schedule 1 formulas, convert to grams if using equivalence, and demonstrate commencement at least 10 years before clinical onset and, if smoking ceased, onset within 25 years of cessation.
   • Radiation (s9(2)): commission dose reconstruction compliant with the ARPANSA Guide "as in force on 2 August 2017" per Schedule 1. The report must calculate cumulative equivalent dose to the stomach and show at least 0.1 sievert received at least five years before onset.
   • H. pylori or EBV infection (s9(3), s9(15)): obtain microbiology, histology, serology or specialist notes demonstrating infection and dates consistent with the required 10‑year lead time.
   • Occupational asbestos or crystalline silica exposure (s9(13)-(14), s9(20)-(21)): secure employment records, rosters, task descriptions, safe work method statements, and expert industrial hygiene reports calculating cumulative exposure hours and classifying exposures as enclosed or open environments. Where disturbance of contaminated debris might be alleged, obtain contemporaneous incident reports.
   • Dietary factors (s9(7)-(11)): compile diet histories, contemporaneous health records, or population-specific diet evidence; get an expert dietician report to convert frequency claims into gram/day exposures and demonstrate sustained exposure within the required five‑year blocks inside the 20‑year window.
   • PPI use (s9(19)): provide pharmacy dispensing records and GP or specialist notes showing continuous PPI use for at least 1 year within the 5 years before onset and cessation at least 1 year before onset.
   • Diabetes, gastric ulcer, chronic atrophic gastritis, autoimmune disease (s9(4), s9(16)-(18)): gather specialist letters, biochemical data, endoscopy and histology reports showing timing and duration conforming to the thresholds.

4. Demonstrate relationship to relevant service: For any factor relied upon, assemble service records, deployment histories, Unit diaries, and contemporaneous medical or occupational records to show how the exposure or condition was related to the person’s relevant service category as defined in Schedule 1 (operational, peacekeeping, hazardous, British nuclear test defence, warlike or non‑warlike service). The Statement requires that the factor be related to relevant service (s10(1)). For example, show that asbestos exposure occurred while executing duties during service rather than in purely civilian employment.

5. For radiation dose: ensure the expert uses the ARPANSA Guide as at 2 August 2017. The Schedule requires that methodology (Schedule 1); submissions using different dose-calculation methodology risk non‑compliance.

6. Resolve cross-references to other SOPs: If a factor refers to another disease (for which there is a separate SOP), find the current version of that SOP and ensure the evidence satisfies its terms (s11). For instance, if a factor depends on previous evidence demonstrating a different disease with its own SOP, follow that SOP’s evidentiary rules.

7. Address factor 9(23) carefully: If relying on inability to obtain appropriate clinical management, confirm the chronology conditions in s10(2): the neoplasm must have been suffered or contracted before or during but not arising out of relevant service. Gather evidence of attempts to obtain care, denial or barriers to access, and timelines showing clinical worsening after failed attempts at management.

8. Assemble corroborating third‑party records: Because many thresholds are quantitative and long-term, secondary sources are often decisive. These include workplace exposure records, pharmacy dispensing histories, specialist consult letters, pathology, microbiology databases, service records, payroll or roster documents, and contemporaneous diaries. Identify and subpoena such records early.

9. Use specialist experts who apply the instrument’s definitions and methods: Medical, occupational hygiene, radiation dosimetry and diet/exposure experts should be instructed to apply the Statement’s definitions (Schedule 1). Expert reports should explicitly state they have used the RMA Statement as the assessment frame and should produce calculations and timelines that directly map to the s9 thresholds and the Schedule definitions.

10. Prepare for challenges on "clinical onset" and exposure quantification: Be ready to justify onset selection and exposure calculations under cross‑examination or administrative scrutiny. Provide methodological appendices in expert reports that show conversions (for example, pack-year calculations using Schedule 1 gram equivalences, or conversion of drinking patterns to total kilograms of alcohol using 10 grams per standard drink).

11. Documentation of diet and lifestyle: For diet-related factors (preserved vegetables, fermented soy, processed meat), contemporaneous records are rarely abundant. Use consistent dietitian interviews, family statements, cultural or regional diet evidence, and any available records. Where possible, triangulate claims , for example, workplace canteen menus, food logs, or cultural testimony.

12. Ensure clarity on non-cardia/cardia classification: Where an expert opinion is required to classify tumour site, ensure pathology explicitly comments on cardiac glands, parietal and chief cells, as required by the Schedule.

13. Where evidence is lacking, consider alternative factors: Because the Statement only requires at least one factor, if evidence for one factor is poor, look for other factors that are easier to substantiate. For example, instead of relying on long-term dietary recall, a claimant might rely on documented diabetes of 5+ years duration or H. pylori infection.

14. Keep procedural records and contemporaneous affidavits: Assemble a timeline and supporting affidavit material explaining why certain records are missing and attempts made to obtain them. Administrative decision-makers will weigh the available evidence against the Statement’s thresholds.

15. Monitor linked SOPs and technical guides: Because the Statement defers to other Statements "in force from time to time" (s11) and to a dated ARPANSA methodology, periodically check for updated SOPs and the potential need to use the current ARPANSA Guide if a new RMA Statement adopts that change.

Following these steps will structure a claim to align with the Statement’s requirements. The central compliance challenge is documentary: quantifying exposures and their timing to meet the Statement’s numeric thresholds and then connecting those exposures to the person’s relevant service record. Expert reports must be prepared to the precise definitions and calculation methods stated in the instrument.